3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Gynecologic
2
Breast
2
Thoracic
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Glioblastoma
8
Brain Neoplasms
5
Neoplasms
4
Glioma
3
Medulloblastoma
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Ketosis
1
Insulin Resistance
1
Gliosarcoma
1
Diabetes Mellitus
1
Colonic Neoplasms
1
Cognitive Dysfunction
1
Chondrosarcoma
1
Cholangiocarcinoma
1
Astrocytoma
1
Interventions
Oxaliplatin
5
Radiotherapy
3
Leucovorin
3
Irinotecan
3
Erlotinib Hydrochloride
3
Cetuximab
3
Bevacizumab
3
selpercatinib
2
cediranib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Fluorouracil
2
Docetaxel
2
ulixertinib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
temsirolimus
1
tanespimycin
1
sargramostim
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
oblimersen
1
motexafin gadolinium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Metformin
×
CNS
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn